Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab in Limited Disease Small-cell Lung Cancer (ACHILES)
NCT03540420Phase 2Active, not recruiting
- Sponsor
- Norwegian University of Science and Technology
- Start
- Jul 2018
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of atezolizumab in small cell lung cancer (SCLC), sponsored by Norwegian University of Science and Technology. Started Jul 2018; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03540420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03540420.